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insulin resistance showed a close relationship with post-
prandial hyperlipidemia in CAD patients. Diabetic, but not 
prediabetic state, may be a risk for postprandial impaired 
lipid metabolism in CAD patients.
Keywords Diabetes · Postprandial hyperlipidemia · 
Hyperinsulinemia · Coronary artery disease · Insulin 
resistance
Introduction
The importance of hyperlipidemia, especially elevated 
serum levels of low-density lipoprotein cholesterol (LDL-
C), has been established as a risk factor for cardiovascular 
disease [1]. Although the direct effect of serum triglycer-
ide (TG) on atherosclerotic lesion formation has been still 
unclear, recent meta-analysis and epidemiologic studies 
have revealed that elevated serum levels of TG are asso-
ciated with the development of coronary artery disease 
(CAD) independent of other coronary risk factors [2, 3]. 
Postprandial hyperlipidemia characterized by pronounced 
and prolonged serum levels of TG, has been shown to play 
an important role in progression or vulnerability of coro-
nary arterial plaque [4]. Not only postprandial hyperlipi-
demia but also hyperinsulinemia has been reported as the 
metabolic condition that could predispose individuals to the 
development of atherosclerosis and CAD [5, 6].
Although type 2 diabetes mellitus (T2DM) is a well-
known potent risk factor for the development of CAD, little 
is known the relationship between postprandial lipid dys-
metabolism and glycemic state in patients with CAD. In 
the present study, we examined whether a significant cor-
relation existed between the severity of glycemic state and 
the degree of postprandial lipidemic responses for studying 
Abstract Both postprandial hyperlipidemia and hyper-
insulinemia have been thought to play an important role 
in the development of atherosclerosis, and to be a potent 
risk factor for cardiovascular event. To examine effects of 
glycemic state on postprandial hyperlipidemia and hyper-
insulinemia in patients with coronary artery disease (CAD), 
a total of 112 consecutive male patients with angiographi-
cally confirmed CAD were loaded with a high-fat and 
high-glucose test meal. CAD patients were divided into 
three groups as “non-diabetic”, “prediabetic”, and “dia-
betic” CAD groups. The serum triglyceride (TG) and 
remnant-like particle cholesterol (RLP-C) levels at the 6th 
hour in diabetic CAD group showed significantly higher 
than non-diabetic CAD group, and the incremental area 
under the curves (iAUCs) of these levels in diabetic CAD 
group were significantly greater than non-diabetic CAD 
group (TG, P = 0.0194; RLP-C, P = 0.0219). There were 
no significant differences in the iAUCs of TG or RLP-C 
between prediabetic and non-diabetic CAD group. The 
AUCs of plasma insulin levels or insulin resistance index 
(IRI): (AUCs of insulin) × (AUCs of glucose) as the 
insulin resistance marker were greater in diabetic CAD 
group than non-diabetic CAD group (insulin, P = 0.0373; 
IRI, P = 0.0228). The AUCs of serum TG or RLP-C lev-
els showed a correlation with the AUCs of plasma insu-
lin (AUC-TG, r = 0.5437, P < 0.0001; AUC-RLP-C, 
r = 0.6847, P < 0.0001), and they correlated well with the 
insulin resistance index (AUC-TG, r = 0.7724, P < 0.0001; 
AUC-RLP-C, r = 0.7645, P < 0.0001). We found that the 
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the impact of diabetic condition on postprandial hyperlipi-
demia or hyperinsulinemia in patients with CAD.
Methods
Study patients
A total of 112 consecutive male patients with stable angina 
pectoris (mean age 66.8 ± 7.9 years) who were angiograph-
ically confirmed CAD and fulfilled the following exclusion 
criteria, were loaded with a high-fat and high-glucose test 
meal at Iwate Prefectural Central Hospital from January 
2013 to June 2014: (1) body mass index (BMI) > 25.0; (2) 
T2DM with insulin therapy; (3) gastrointestinal disease 
limiting drug absorption or partial ileal bypass; (4) major 
surgery within 6 months prior to enrollment or concomi-
tant inflammatory disease or malignant tumors; (5) con-
gestive heart failure or active liver disease or hepatic dys-
function defined as alanine aminotransferase or aspartate 
aminotransferase > normal range; (6) concurrent therapy 
with long-term immunosuppressants; (7) familial hyper-
cholesterolemia; (8) taking lipid lowering medications 
without statins (e.g., ezetimibe, cholestyramine, niacin, or 
fibrates) and/or eicosapentaenoic acid or docosahexaenoic 
acid therapy.
Ethics
This study was conducted according to the principles 
expressed in the Declaration of Helsinki. Written informed 
consent was obtained from the subjects and the study 
design was approved by the ethics committee of the Iwate 
Prefectural Central Hospital.
Definitions
Patients with stable angina pectoris were defined as cardiac 
ischemic patients who had a history of myocardial infarc-
tion, coronary artery bypass, percutaneous coronary inter-
vention with or without stenting, or previous angiographi-
cally proved stenotic lesion ≥75 % in a major epicardial 
coronary artery. They were also diagnosed as stable condi-
tion when chest pain was brought on by exertion, resolved 
under nitrate-therapy and not changed in its characteristics 
(frequency, severity, duration, time of appearance and pre-
cipitating factors) for the previous 60 days [7].
Patients with CAD were classified into three groups 
(non-diabetic, prediabetic and diabetic groups) accord-
ing to glycated hemoglobin A1c (HbA1c) levels and fast-
ing plasma glucose (FPG) levels in accordance with 2010 
American Diabetes Association (ADA) Guidelines [8, 9]. 
Non-diabetic patients were defined as patients without 
dysglycemia which was indicated by the presence of either 
T2DM or prediabetes. Diagnosis of T2DM was made 
according to ADA criteria of a FPG level of ≥126 mg/dL, 
HbA1c ≥ 6.5 %, or current use of hypoglycemic agents. 
Prediabetes was indicated by a FPG level of 100–125 mg/
dL or a HbA1c level of 5.7–6.4 % without T2 DM.
Study design
For fat loading, all patients were given an oral high-fat 
and high-glucose meal for breakfast after overnight fast-
ing for at least 12 h (named as cake sále test). This cake 
sále consisted of high-fat and high-glucose [1003 kcal; 
protein, 28.6 g (11.4 %); lipids, 62.4 g (56.0 %); carbo-
hydrate, 80.7 g (32.2 %); cholesterol, 320.5 mg (0.4 %)] 
and its ingredients were similar to those of an American 
fast-food meal (Big Mac Cheeseburger® with French fries, 
Coca-Cola®) which was one of the most popular food in 
the world [10]. Patients were requested to eat this high-fat 
and high-glucose meal (cake sále) in 30 min. In all patients, 
this cake sále test was performed in stable condition. Blood 
samples were obtained by venipuncture during the fast-
ing state just before the cake sále test and 0, 2, 4, and 6 h 
after the test. Sera were separated immediately after blood 
collection by low-speed centrifugation (at 3000 rpm for 
15 min at 4 ºC) and stored at −80 ºC until measurements. 
Serum levels of total cholesterol (TC) and TG were deter-
mined by enzymatic methods, serum LDL-C and high-
density lipoprotein cholesterol (HDL-C) levels by a direct 
method, serum malondialdehyde-modified LDL (MDA-
LDL) levels by a sandwich ELISA method, serum apolipo-
protein A-I (Apo A-I) and apolipoprotein B (Apo B) levels 
by an immunoturbidity method, and serum remnant-like 
particle cholesterol (RLP-C) levels by the immunoaffin-
ity isolation method, respectively, at a contract laboratory 
(SRL Co., Ltd., Tokyo, Japan). Serum LDL-C levels were 
determined by direct measurement and not by calculation 
by the Friedewald formula, since the postprandial TG lev-
els were predicted to 400 mg/dL.
Plasma glucose and insulin levels were also measured 
for the assessment of glucose metabolism before and after 
a meal load. Plasma insulin levels were determined by a 
chemiluminescent enzyme immunoassay method, HbA1c 
levels by a high-performance liquid chromatography 
method, respectively, at the laboratory of our hospital.
Each fasting values were obtained before the cake sále 
test. All samples were treated in accordance with the Hel-
sinki Declaration.
Insulin resistance markers
In the present study, the following insulin resistance mak-
ers were measured: (1) fasting insulin levels, (2) insulin 
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levels at 2 h after the cake sále test, (3) the area under the 
curve (AUC) of insulin during the test, (4) the insulin 
resistance index: [(AUCs of insulin) × (AUCs of glucose)], 
(5) the homeostasis model assessment of insulin resistance 
(HOMA-IR). HOMA-IR was calculated as [fasting plasma 
glucose (mg/dL) × fasting plasma insulin (μIU/mL)]/405 
[11, 12]. The AUC was calculated by the trapezoidal 
method, and incremental AUC (iAUC) was calculated as 
total AUC minus the area under the basal value.
Statistical analysis
All values are expressed as mean ± standard deviation for 
continuous variables and as numbers and percentages for 
categorical variables. Differences between two groups were 
assessed using Student’s unpaired t test or Mann–Whit-
ney’s U test for continuous variables and Chi-square test or 
Fisher’s exact test for categorical variables, as appropriate. 
One-way analysis of variance followed by Tukey–Kramer 
honestly significant difference test was used to examine 
differences among multiple groups. Correlation between 
the two parameters was determined by simple linear regres-
sion analysis. A two-sided P value of less than 0.05 was 
considered statistically significant. All statistical analyses 




Table 1 shows the baseline characteristics of the patients 
(n = 112) divided into three groups: 32 patients (29 %) 
Table 1  Baseline characteristics in patients
Values for continuous variables are shown as mean ± SD; categoric variables are represented by number (percentage, %)
BMI body mass index, HbA1c hemoglobin A1c, LDL low-density lipoprotein, HDL high-density lipoprotein, RLP remnant lipoprotein, MDA 
malondialdehyde-modified
# Difference among three groups analyzed by one-way analysis of variance (ANOVA) for continuous variables, chi-square test for categoric 
variables
Variable Non-diabetic CAD group 
(n = 32)
Prediabetic CAD group 
(n = 47)
Diabetic CAD group 
(n = 33)
P value#
Age (years) 68.5 ± 6.5 66.1 ± 8.6 66.8 ± 8.0 0.8223
Weight (kg) 63.1 ± 4.9 61.0 ± 6.0 62.6 ± 8.1 0.7472
Height (cm) 163.3 ± 3.0 163.2 ± 4.9 166.5 ± 8.3 0.3463
BMI (kg/m2) 23.1 ± 1.4 22.9 ± 1.6 22.5 ± 2.1 0.7323
Hypertension (n) (%) 20 (63) 30 (64) 22 (67) 0.5864
Blood pressure (mmHg)
Systolic 136.2 ± 8.1 127.6 ± 19.7 123.9 ± 17.1 0.2852
Diastolic 69.7 ± 12.8 77.4 ± 10.8 71.8 ± 15.2 0.4769
Current or ex-smokers (n) (%) 21 (66) 33 (70) 23 (70) 0.6271
Glucose markers
HbA1c (%) 5.4 ± 0.2 6.0 ± 0.2 7.1 ± 0.8 <0.0001
Fasting plasma glucose (mg/dL) 90.5 ± 14.3 103.8 ± 14.6 138.7 ± 9.6 0.0002
Fasting plasma insulin (μIU/mL) 6.1 ± 3.1 6.4 ± 3.8 8.4 ± 3.7 0.1102
Fasting plasma C-peptide (ng/mL) 1.4 ± 0.5 1.8 ± 0.9 2.6 ± 0.5 0.0808
Use of stain (n) (%) 32 (100) 47 (100) 33 (100) 1.0000
Lipid markers
Total cholesterol (mg/dL) 159.7 ± 31.4 171.6 ± 29.4 175.5 ± 22.1 0.3653
Triglyceride (mg/dL) 122.7 ± 40.5 141.2 ± 74.7 140.3 ± 76.8 0.9845
LDL cholesterol (mg/dL) 95.8 ± 27.9 100.5 ± 30.4 100.5 ± 20.1 0.9054
HDL cholesterol (mg/dL) 46.5 ± 11.5 51.9 ± 12.7 55.6 ± 16.8 0.3710
RLP cholesterol (mg/dL) 4.3 ± 1.3 4.9 ± 2.5 4.9 ± 2.6 0.6630
MDA LDL (U/L) 98.7 ± 36.0 107.3 ± 28.6 114.3 ± 32.6 0.4975
Apolipoprotein A-I (mg/dL) 121.7 ± 19.0 137.5 ± 26.6 139.7 ± 30.9 0.3799
Apolipoprotein B (mg/dL) 82.5 ± 18.8 85.0 ± 22.4 86.9 ± 15.7 0.8439
1449Heart Vessels (2016) 31:1446–1455 
1 3
in non-diabetic CAD group; 47 patients (42 %) in pre-
diabetic CAD group; 33 patients (29 %) in diabetic CAD 
group. The levels of HbA1c and FPG were 5.4 ± 0.2 %, 
90.5 ± 14.3 mg/dL in non-diabetic CAD group; 
6.0 ± 0.2 %, 103.8 ± 14.6 mg/dL in prediabetic CAD 
group; 7.1 ± 0.8 %, 138.7 ± 9.6 mg/dL in diabetic CAD 
group, respectively. All patients had received statins, and 
no significant differences in lipid markers were observed 
such as TG, LDL-C, HDL-C, and RLP-C among three 
groups. Patients with BMI level >25.0 were excluded in 
the present study, and there was no significant difference 
in body size. There were also no significant differences in 
age, blood pressure, and the incidence of hypertension or 
smoking among three groups.
Postprandial changes of lipid and glucose markers
The changes of lipid and glucose markers in the cake sále 
test are summarized in Table 2. In all the three groups, 
the serum TG and RLP-C levels showed the significant 
changes during the test. Other lipid markers did not show 
any meaningful changes from the baseline. There were also 
significant changes in plasma glucose and insulin levels 
during the test in each group.
Figure 1a shows the changes in serum TG levels after 
the fat loading test in three groups. The values of serum 
TG in diabetic group at the 4th and 6th hour were signifi-
cantly higher than those in non-diabetic group (4th hour: 
355.9 ± 114.7 vs. 232.2 ± 71.8 mg/dL, P = 0.0083; 6th 
hour: 364.8 ± 127.3 vs. 215.7 ± 64.6 mg/dL, P = 0.0061). 
There were no significant differences in serum TG values at 
the 4th and 6th hour between diabetic and prediabetic CAD 
group (4th hour: 355.9 ± 114.7 vs. 287.6 ± 110.9 mg/dL, 
P = 0.0847; 6th hour: 364.8 ± 127.3 vs. 291.2 ± 135.6 mg/
dL, P = 0.1864). There were also no significant differ-
ences in serum TG values at the 4th and 6th hour between 
prediabetic and non-diabetic CAD group (4th hour: 
287.6 ± 110.9 vs. 232.2 ± 71.8 mg/dL, P = 0.1184; 6th 
hour: 291.2 ± 135.6 vs. 215.7 ± 64.6 mg/dL, P = 0.0749).
The iAUCs of serum TG levels in diabetic CAD group 
were significantly greater than those in non-diabetic CAD 
group (P = 0.0194). There were no significant differences 
in iAUCs of serum TG levels between diabetic and predia-
betic CAD group (P = 0.0647), or prediabetic and non-dia-
betic CAD group (P = 0.1576) (Fig. 1b).
As shown in Fig. 1c, the changes in serum RLP-C lev-
els after the fat loading test for three groups were similar 
to those in serum TG levels. The values of serum RLP-C 
levels in diabetic CAD group at the 4th and 6th hour were 
significantly higher than those in non-diabetic CAD group 
(4th hour: 14.6 ± 4.0 vs. 8.2 ± 2.4 mg/dL, P = 0.0064; 6th 
hour: 16.9 ± 4.4 vs. 7.6 ± 2.2 mg/dL, P = 0.0057). There 
were no significant differences in serum RLP-C levels at the 
4th and 6th hour between prediabetic and diabetic or non-
diabetic CAD group. The iAUCs of serum RLP-C levels in 
diabetic CAD group were significantly greater than those 
in prediabetic and non-diabetic CAD groups (P = 0.0431, 
0.0219, respectively). There were no significant differences 
in iAUCs of serum RLP-C levels between prediabetic and 
non-diabetic CAD group (P = 0.1871) (Fig. 1d).
As shown in Fig. 1e, g, the serum glucose and insulin 
levels in each group increased postprandially and reached 
peak levels at the 2nd hour, and then returned to baseline 
levels by the 4th or 6th hour after the test. Compared with 
non-diabetic CAD group, diabetic CAD group showed that 
the plasma insulin levels at the 2nd hour after the test were 
significantly higher (P = 0.0067) (Fig. 1g). The AUCs of 
plasma insulin levels as the insulin resistance marker were 
greater in diabetic CAD group than in non-diabetic CAD 
group (145.3 ± 57.9 vs. 92.6 ± 58.7, P = 0.0373) (Fig. 1f). 
The insulin resistance index: (AUCs of insulin) × (AUCs 
of glucose) was also greater in diabetic CAD group than 
non-diabetic CAD group (11,943 ± 8730 vs 6938 ± 4587, 
P = 0.0228) (Fig. 1h).
Relationship between lipid markers and insulin 
resistance markers
The data on insulin resistance markers in each group are 
summarized in Table 3. There were significant differences 
in insulin resistance markers except fasting plasma insulin 
levels among three groups, and diabetic CAD group had 
higher levels of insulin resistance than non-diabetic CAD 
group (HOMA-IR, 2.1 ± 1.3 vs. 1.2 ± 0.9, P = 0.0075; 
insulin levels at the 2nd hour, 33.8 ± 8.5 vs. 23.7 ± 7.1, 
P = 0.0183).
Figure 2 shows the relationship between lipid markers 
and insulin resistance markers in the cake sále test. The 
AUCs of serum TG or RLP-C levels showed a correlation 
with the AUCs of plasma insulin (AUC-TG, r = 0.5437, 
P < 0.0001; AUC-RLC-P, r = 0.6847, P < 0.0001) (Fig. 2a, 
b), and furthermore, they correlated well with the insu-
lin resistance index: (AUCs of insulin) × (AUCs of glu-
cose) (AUC-TG, r = 0.7724, P < 0.0001; AUC-RLC-P, 
r = 0.7645, P < 0.0001) (Fig. 2c, d). There did not exist a 
definite correlation between insulin resistance markers and 
such lipid markers as HOMA-IR, fasting insulin, insulin 
levels at the 2nd hour (data not shown).
Discussion
The main findings of the present study were that (1) the 
magnitude of postprandial serum TG or RLP-C accumula-
tion, which was shown as the area under the TG or RLP-C 
curve over 6 h after the fat loading test, was greater in 
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diabetic CAD group than in non-diabetic or prediabetic 
CAD group, and (2) it correlated well with insulin resist-
ance markers: the AUCs of insulin and the insulin resist-
ance index described as [(AUCs of insulin) × (AUCs of 
glucose)].
Hyperlipidemia has been established as a major inde-
pendent risk factor for CAD and therapies aimed at 
reducing serum LDL-C level are considered to be an essen-
tial element of any attempt to prevent CAD; however, the 
role of hypertriglyceridemia is not fully understood. Not 
only fasting but also non-fasting hypertriglyceridemia 
have shown as an important factor in the development 
of atherosclerosis and closely related to the occurrence 
of cardiovascular events [3]. Non-fasting, postprandial 
Table 2  Changes of lipid and glucose markers after the load test
Values are shown as mean ± SD
LDL low-density lipoprotein, HDL high-density lipoprotein, RLP remnant lipoprotein, MDA malondialdehyde-modified
† P <0.05, ‡ P <0.01, § P <0.005, ¶ P < 0.001 comparing with the value before the load test in the same group
Before After
0h 2h 4h 6h
Triglyceride (mg/dL)
Non-diabetic group (n = 32) 122.7 ± 40.5 125.7 ± 43.4 163.2 ± 65.4 232.2 ± 71.8† 215.7 ± 64.6†
Prediabetic group (n = 47) 141.2 ± 74.7 146.9 ± 78.5 198.5 ± 84.5 287.6 ± 110.9‡ 291.2 ± 135.6‡
Diabetic group (n = 33) 140.3 ± 76.8 139.2 ± 82.7 224.3 ± 85.2¶ 355.9 ± 114.7¶ 364.8 ± 127.3¶
LDL cholesterol (mg/dL)
Non-diabetic group (n = 32) 95.8 ± 27.9 97.4 ± 26.7 91.0 ± 26.8 89.2 ± 24.4 91.0 ± 26.2
Prediabetic group (n = 47) 100.5 ± 30.4 101.4 ± 32.6 95.3 ± 29.3 93.8 ± 29.3 94.8 ± 27.6
Diabetic group (n = 33) 100.5 ± 20.1 101.5 ± 20.1 94.5 ± 18.4 91.9 ± 18.1 93.9 ± 18.8
HDL cholesterol (mg/dL)
Non-diabetic group (n = 32) 46.5 ± 11.5 48.0 ± 12.3 44.6 ± 11.7 43.5 ± 10.5 44.5 ± 11.1
Prediabetic group (n = 47) 51.9 ± 12.7 53.1 ± 11.6 50.1 ± 11.3 48.7 ± 10.4 49.8 ± 11.8
Diabetic group (n = 33) 55.6 ± 16.8 56.4 ± 17.6 52.4 ± 16.5 51.3 ± 16.3 52.0 ± 17.0
RLP cholesterol (mg/dL)
Non-diabetic group (n = 32) 4.3 ± 1.3 4.4 ± 1.4 5.7 ± 2.2‡ 8.2 ± 2.4‡ 7.6 ± 2.2†
Prediabetic group (n = 47) 4.9 ± 2.5 5.1 ± 2.7 7.0 ± 2.9† 10.1 ± 3.9§ 10.3 ± 4.7§
Diabetic group (n = 33) 4.9 ± 2.6 4.9 ± 2.8 7.9 ± 2.9¶ 14.6 ± 4.0¶ 16.9 ± 4.4¶
MDA LDL (U/L)
Non-diabetic group (n = 32) 98.7 ± 36.0 105.7 ± 38.0 93.2 ± 28.0 89.0 ± 27.4 90.3 ± 33.6
Prediabetic group (n = 47) 107.3 ± 28.6 112.5 ± 31.4 100.1 ± 30.0 101.9 ± 32.0 104.2 ± 32.3
Diabetic group (n = 33) 114.3 ± 32.6 117.4 ± 33.3 104.0 ± 26.8 103.3 ± 28.8 109.1 ± 28.9
Apolipoprotein A-I (mg/dL)
Non-diabetic group (n = 32) 121.7 ± 19.0 125.5 ± 20.6 118.2 ± 19.1 118.3 ± 15.1 119.5 ± 17.7
Prediabetic group (n = 47) 137.5 ± 26.6 139.5 ± 27.5 132.2 ± 24.0 132.0 ± 22.2 132.2 ± 24.7
Diabetic group (n = 33) 139.7 ± 27.8 141.9 ± 33.2 135.4 ± 32.0 135.3 ± 31.3 136.3 ± 33.1
Apolipoprotein B (mg/dL)
Non-diabetic group (n = 32) 82.5 ± 18.8 84.2 ± 18.4 79.2 ± 18.0 80.2 ± 17.2 80.3 ± 18.2
Prediabetic group (n = 47) 85.0 ± 22.4 86.7 ± 22.9 82.0 ± 20.9 82.4 ± 22.2 82.3 ± 21.1
Diabetic group (n = 33) 86.9 ± 15.7 87.4 ± 15.5 83.5 ± 14.1 84.0 ± 14.3 84.8 ± 14.1
Glucose (mg/dL)
Non-diabetic group (n = 32) 90.5 ± 14.3 113.3 ± 21.1¶ 101.1 ± 28.7 95.5 ± 11.5 94.0 ± 5.7
Prediabetic group (n = 47) 103.8 ± 14.6 121.9 ± 22.4¶ 123.8 ± 31.9¶ 97.1 ± 15.7 97.7 ± 7.6†
Diabetic group (n = 33) 138.7 ± 9.6 158.4 ± 36.2 182.0 ± 35.7† 129.0 ± 26.1 117.5 ± 19.8
Insulin (μIU/mL)
Non-diabetic group (n = 32) 6.1 ± 3.1 21.8 ± 6.1§ 23.7 ± 7.1§ 14.0 ± 7.8† 6.4 ± 4.5
Prediabetic group (n = 47) 6.4 ± 3.8 20.6 ± 12.3¶ 28.1 ± 7.6¶ 13.3 ± 6.9¶ 7.6 ± 4.3
Diabetic group (n = 33) 8.4 ± 3.7 24.7 ± 8.5¶ 33.8 ± 7.9¶ 20.8 ± 8.8¶ 10.5 ± 6.9
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Fig. 1  Postprandial changes in serum TG (a), RLP-C(C), glucose (e), 
and insulin (g) levels after the fat loading test; comparison of iAUCs 
for postprandial serum TG (b), RLP-C(D); comparison of AUCs 
for plasma insulin (f) levels and insulin resistance index (h) during 
the test. Data are expressed as mean ± SD. †P  < 0.05, ‡P  < 0.01, 
§P < 0.005, ¶P < 0.001 comparing with the value at the same time 
points in non-diabetic CAD group. TG triglycerides, RLP-C remnant-
like particle cholesterol, AUC area under the curve, iAUC incremen-
tal area under the curve. Insulin resistance index is one of the insulin 
resistance markers as calculated by (AUCs of insulin) × (AUCs of 
glucose)
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hypertriglyceridemia is characterized by accumulation of 
excess TG-rich lipoproteins and their partially hydrolyzed 
products such as chylomicron (CM) remnant (CM-R) and 
very low-density lipoprotein (VLDL) remnant (VLDL-
R) during the postprandial period. For estimation of the 
risk for CAD, the measurement of lipid parameters such 
as serum TG and RLP-C may be more important in non-
fasting state such as postprandial condition than in fast-
ing state. Although postprandial hyperlipidemia has been 
reported to be a predisposing factor in coronary events 
[3, 4], little information has been available regarding the 
observation of postprandial kinetic responses to a fat load 
in CAD patients confirmed by angiography. In the present 
study, the levels of serum TG and RLP-C kept rising dur-
ing 6 h after the load and the kinetics of these serum levels 
were similar among three CAD groups. These results were 
compatible with the previous reports which were obtained 
from the relatively small number of CAD patients [13, 14].
Table 3  Insulin resistance markers
Values are shown as mean ± SD
HOMA-IR homeostasis model assessment of insulin resistance, AUC area under the curve
† P < 0.05, ‡ P < 0.01 comparing with the value in non-diabetic group
Non-diabetic CAD group 
(n = 32)
Prediabetic CAD group 
(n = 47)
Diabetic CAD group 
(n = 33)
HOMA-IR 1.2 ± 0.9 1.7 ± 1.0 2.1 ± 1.3‡
Fasting insulin (µIU/mL) 6.1 ± 3.1 6.4 ± 3.8 8.4 ± 3.7
2 h insulin (µIU/mL) 23.7 ± 7.1 28.1 ± 7.6 33.8 ± 7.9‡
AUC0–6h insulin (µIU/mL h) 92.6 ± 58.7 105.1 ± 64.3 145.3 ± 57.9†
AUC insulin × AUC glucose 
(µIU/L mg/L h2)
6938 ± 4587 9573 ± 3942 11943 ± 8730†
Fig. 2  Correlations between the value of AUCs for postprandial 
serum TG or RLP-C levels and those for postprandial plasma insulin 
or insulin resistance index (IRI) in CAD groups. a TG vs insulin, b 
RLP-C vs insulin, c TG vs IRI, d RLP-C vs IRI. TG triglycerides, 
RLP-C remnant-like particle cholesterol, AUC area under the curve. 
Insulin resistance index is one of the insulin resistance markers as 
calculated by (AUCs of insulin) × (AUCs of glucose)
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Dyslipidemia characterized by high levels of serum 
fasting TG and low levels of serum HDL-C is common in 
patients with T2DM [15]. Moreover, it has been known that 
these patients showed high and prolonged postprandial lipi-
demia after meals [16]. In the present study, CAD patients 
were divided into three groups (non-diabetic, prediabetic, 
diabetic groups), depending on the degree of diabetic con-
dition and then the comparisons were made of postpran-
dial lipid and glucose metabolism. Although the different 
responses of serum TG or RLP-C levels after the load were 
shown between patients with T2DM and normal control 
subjects [15], there is limited information on postpran-
dial lipid metabolism in different diabetic condition. To 
our knowledge, this is the first report as to the postpran-
dial lipid responses in CAD patients, depending on differ-
ent diabetic conditions. It was found that the magnitude of 
postprandial serum TG or RLP-C accumulation was signifi-
cantly greater in diabetic CAD group when compared with 
prediabetic or non-diabetic CAD group, whereas it was 
no different between prediabetic and non-diabetic CAD 
group. Although we analyzed serum RLP-C levels after 
the load, the measurement of remnant lipoprotein choles-
terol (RemL-C) which is more direct marker for CM-R and 
VLDL-R might provide valuable additional information in 
the present study.
It has been hypothesized that two pathways (endogenous 
and exogenous pathways) could induce the postprandial 
lipid accumulations in patients with T2DM. Endogenous 
pathway is characterized by an increased hepatic VLDL 
production, as a result from increased free-fatty acid (FFA) 
release from adipose tissue and inefficient suppression of 
hepatic VLDL release by insulin. Patients with T2DM has 
been reported to show the diminution of antilipolytic effect 
by insulin, leading to a higher FFA flux from adipose tis-
sue [17]. Exogenous pathway is closely related with an 
increase of lipid absorption from the intestine in patients 
with T2DM. Animal models using streptozotocin-induced 
diabetic rats showed an increased intestinal TG produc-
tion and an increased intestinal absorption of cholesterol 
[18]. In patients with T2DM, the absorption of cholesterol 
was shown to be higher in CAD patients than non-CAD 
patients [19]. Epidemiological study also demonstrated that 
impaired cholesterol homeostasis, reflected by lower syn-
thesis markers such as lathosterol and higher absorption 
markers such as campesterol, was a highly significant inde-
pendent predictor of CAD in the Framingham Offspring 
Study Cycle-6 participants including approximately 30 % 
of patients with DM [20]. Which pathway could contrib-
ute significantly to the elevated lipid levels after the meal 
in CAD patients with T2DM? Recently, Masuda et al. [21] 
measured Apo B-48 and Apo B-100 levels separately in 
fasting and postprandial state to assess the endogenous and 
exogenous pathway independently, and they reported that 
postprandial increase in serum TG and RLP-C levels was 
mainly due to increase of CM and CM-R, but not VLDL 
and VLDL-R. Unfortunately, we could not answer the 
above question in the present study because we could not 
distinguish between the changes of endogenous pathway 
and those of exogenous pathway. Measurement of not only 
serum TG or RLP-C levels but also lipid markers related 
with exogenous pathway such as Apo B-48, CM, or CM-R 
would contribute to better understanding of the pathophysi-
ological differences in the exogenous versus endogenous 
pathway.
Our results showed that the postprandial responses 
of lipid markers were similar between pre- and non-
diabetic CAD group, and that the magnitude of post-
prandial serum TG or RLP-C accumulation was no sig-
nificantly different between these two groups. In the 
present study, prediabetic state was defined as impaired 
fasting glucose (IFG) by FPG levels (100–125 mg/dL) 
and HbA1c levels (5.7–6.4 %) according to 2010 ADA 
Guidelines [8], not as impaired glucose tolerance (IGT) 
by 2-h 75 g oral glucose tolerance test (OGTT) values 
which could affect glycemic state or insulin resist-
ance as accurately as possible. Addition of the estima-
tion by OGTT would provide more useful information 
about the difference of postprandial lipid metabolism 
between prediabetic patients with and without IGT in 
the present study; however, there was a need to sim-
plify screening test for glycemic state so relatively 
large number of patients could be identified earlier and 
more efficiently.
Not only impaired postprandial lipid metabolism but 
also hyperinsulinemia has been thought to play an impor-
tant role in the development of atherosclerosis [22, 23]. 
The postprandial increase of plasma insulin levels after the 
load was shown to be greater in diabetic CAD group than 
non-diabetic or prediabetic CAD group. And the sum of the 
amount of increase of plasma insulin values during the test 
was significantly higher in diabetic CAD group as com-
pared with non-diabetic or prediabetic CAD group. These 
results suggest that diabetic CAD patients show higher 
insulin resistant compared with non- or prediabetic CAD 
patients. There is clinical evidence to indicate that met-
formin which is an oral antidiabetic drug in the biguanide 
class [24], pioglitazone which is an agonist of peroxisome 
proliferator-activated receptor [25], or α-glucosidase inhib-
itor which inhibits the absorption of carbohydrates in the 
gastrointestinal tract [26], reduce the risk of cardiovascular 
events in T2DM patients. The anti-atherosclerotic effect of 
these drugs which reduce insulin resistance might be pro-
duced partially via improvement of postprandial hyperinsu-
linemia and/or hyperlipidemia.
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Study limitations
There are several limitations to the present study. First, 
all subjects of the present study were male patients to 
exclude the hormonal effect by estrogen on postprandial 
lipid metabolism. Second, the present study did not include 
the patients with insulin therapy for excluding the effects 
by exogenous insulin. The postprandial lipid metabolism 
remains unknown in these patients. Third, all patients in 
CAD group were treated with statins. Because the possi-
bility exists that the effective inhibition of hepatic choles-
terol synthesis by statins leads to the increase of intestinal 
absorption of cholesterol [27], more investigation for cho-
lesterol absorption/synthesis markers such as cholesterol or 
lathosterol [28] would provide valuable additional informa-
tion in the present study.
Conclusions
We examined the relationship between the severity of 
glycemic state and the degree of postprandial lipidemic 
responses in CAD patients. Our results suggest that insu-
lin resistance shows a close relationship with postprandial 
hyperlipidemia, and that diabetic state, but not predia-
betic state, may be a risk for postprandial impaired lipid 
metabolism.
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